Tocilizumab as treatment for COVID-19: A systematic review and meta-analysis

doi:10.5662/wjm.v11.i3.95

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5966)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

305

WORD

135

HTML

2756

Figures (1-2)

281

Tables (1-3)

346

Sum=3823

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

291

Download

674

Sum=965

Publishing Process of This Article

Item

Count

Browse

440

Download

738

Sum=1178

May 20, 2021 (publication date) through Jul 5, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Methodology

ISSN

2222-0682

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

World J Methodol. May 20, 2021; 11(3): 95-109
Published online May 20, 2021. doi: 10.5662/wjm.v11.i3.95

Full Size Figure Download Figure

Figure 2 In the primary analysis, mortality was reduced in patients treated with tocilizumab.

Citation: Petrelli F, Cherri S, Ghidini M, Perego G, Ghidini A, Zaniboni A. Tocilizumab as treatment for COVID-19: A systematic review and meta-analysis. World J Methodol 2021; 11(3): 95-109
URL: https://www.wjgnet.com/2222-0682/full/v11/i3/95.htm
DOI: https://dx.doi.org/10.5662/wjm.v11.i3.95